Drug Development Services
Integrated one-stop discovery
Our integrated drug development services are designed to maximize the benefits of our AI and computation-driven platforms for discovering innovative small molecules. We offer clients end-to-end solutions from the initial concept to the pre-clinical candidate stage, specifically accelerating the drug discovery and development process for targets or indications with high potential.
Service offereings
- Our objective is to seamlessly progress drug development projects to the candidate compound stage, prior to GLP (Good Laboratory Practice) toxicology testing.
- Clients work closely with ComMedX to select targets, ensuring alignment between both parties’ goals and expectations.
- ComMedX leverages an interdisciplinary team, including experts in computational chemistry, chemical synthesis, and bioassays, to deliver efficient project management and innovative solutions.
- We conduct regular evaluations of project milestones to maximize market value and allocate resources and equity appropriately.
- Upon reaching key milestones, ComMedX provides flexible options for equity realization, allowing for full or partial liquidation.
- Drug design and synthesis, along with some biologics R&D activities, are conducted in-house at ComMedX. In vivo biological validation is performed by partner organizations or third-party CROs, offering flexible collaboration models to meet the unique requirements of each project.
Why ComMedX
- Interdisciplinary Professional Team: Our projects receive comprehensive, multidimensional professional support.
- End-to-End Support: From target selection to the development of pre-GLP toxicology candidate compounds, we offer seamless, integrated support that coordinates effectively with third-party CROs.
- Flexible Cooperation Models: We provide tailored solutions designed to meet the specific needs of diverse projects.
Business Inquiry
For more information, please send a message to contact@commedx.com
We will get in touch with you as soon as possible.
